In this study we used the parametric survival approach to analyze the survival time of African American breast cancer patients. In research about the survival time of patients, the Cox Proportional Hazard model, a semi-parametric method, is primarily used, but this approach does not rely on the distributional assumptions. The parametric method is more consistent with a theoretical approach compared to a semi-parametric approach. We observe that the survival time of African American breast cancer patients follows the Weibull Probability Distribution. First, we fitted the model to represent the survival ability of the general population (African American women diagnosed with breast cancer), treating everyone the same. Second, we incorporate other patient-specific covariate factors affecting the survival time to predict lifetime of a particular patient, given that her information is fully known.
MOTIVATION
Breast cancer is one of the most dangerous diseases and is the most commonly contracted cancer among women. The American Cancer Society estimated that in the year 2013, about 232,340 new cases of invasive breast cancer would be diagnosed; and about 39,620 women would die because of this deadly disease (American Cancer Society).
African Americans are among the races most affected by breast cancer disease.
According to the statistics from the National Cancer Institute, African American women have the second highest rate of breast cancer, only slightly less than white Americans (121.4 compared to 127.4 cases per 100,000 persons). In addition, African American women have the highest death rate of those diagnosed with breast cancer. The five-year survival rate for African American breast cancer is 78% (Sisters Network). This means that for every 100 African American women diagnosed with breast cancer, there are on average 22 people that die within the first 5 years of being diagnosed. Previous studies have also shown that African-American women are more likely to have late-stage breast cancer at diagnosis and shortened survival (Bradley) .
Statistics about breast cancer provided by the National Cancer Institute, such as five-year survival rate, death rates by age group, etc. cannot satisfy human need. Those numbers cannot help us answer essential questions such as: 3. Which treatments are effective to cure breast cancer of a patient with particular age, race, and stage? How much can the treatments lengthen the survival time?
The main purpose of our study is to answer the questions above using information about African American breast cancer patients from the Surveillance Epidemiology and End Results (SEER) database of National Cancer Institute (NCI) from 1973 to 2010. In other words, we evaluate the potential risk factors and determine the best treatment methods that are suitable for the patients to increase the survival time based on their information such as age, tumor size, stage of the disease etc.
According to the National Cancer Institute, important factors affecting the survival of cancer patients are type and location of the cancer, stage of cancer, patient's age, race and overall general health, etc. (National Cancer Institute). The information included in this study includes survival time, cause-specific death classification, age, stage of cancer, types of treatment (radiation, surgery, both radiation and surgery). Specific description of data is presented in Appendix A.
We observe that the survival times of African American breast cancer patients are best characterized by the Weibull probability distributions. The data distribution was fitted using both STATISTICA and SPSS software. The results and validation of those fits are presented in Appendix B and Appendix C. In the next section we derive the model to estimate the survival time based on the Weibull probability distribution and fit the data using SAS statistical software.
MATHEMATICAL DESCRIPTION AND SOLUTION APPROACH
The Weibull probability distribution function is given by: = ( ) = −1 − (λ, α>0, t≥0) with the parameter being θ = (λ, α) (Klein) . Therefore, the survival function is:
The hazard rate is
We want to estimate these two parameters so that the distribution can fit the best to the data, we use the maximum likelihood method (Evans):
Given the independent and identically distributed sample t1, t2… tn (t1, t2… tn ≥0), the joint density function is
However, because the sample is given (from the data), we can treat the function above as a function of . Our job is to define the value of that maximize the probability to experience the given sample ( 1 , 2 , … , ), i.e. maximize L. 6 Since the function ln(x) is increasing on (0, ∞), maximizing ln L is the same as
We can maximize this function by setting ln = 0 and ln = 0
From (8), replace = ∑ =1 to (10) to get
It is difficult to solve this equation normally. However, we can prove that equation (11) has at most one solution of α for any sample of xi (Balakrishnan) .We can use software (SAS) to estimate one solution of α and that solution is the only one.
Consider the LHS a function of α
Using the Cauchy-Schwarz inequality we obtain:
Therefore,
Hence, ′ ( ) ≤ 0. This means that ( ) is a decreasing function and if we can find a solution of (3), that is the only solution.
Once we have the result of α from software (SAS), the value of λ is easily determined from (8).
Nevertheless, the true value of is not always available. In the study of breast cancer, there are events such as patients dropping their treatments, patients dying due to causes different from the breast cancer, etc. These events cause the value of to be censored, but we are still sure that is definitely larger than a certain number (the time between the beginning and the censoring events). This is the right-censored data.
Therefore, we would like to make likelihood estimations for the right-censored data (Klein) . Let δ denote the status of the data (δ = 0 when lifetime T is censored and δ = 1 when the lifetime X is observed). And T is equal to T if the lifetime is observed.
The likelihood function is:
Similar to the non-censor case, we set ln = 0 and ln = 0
And:
This is the same as (11). Therefore, in case we have censored values, we still have the same α. λ is determined by (19).
By using SAS, we obtain the estimate of α = 0.746, the estimate of λ = 0.059. SAS outputs are presented in Appendix D So our probability density function is:
Survival function:
Hazard function:
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Estimation of Variance-covariance matrix for ̂ and ̂
We need to find the three values:
The estimators of λ and α are given by ̂= 1 , and ̂= −̂ (Klein) .
Applying the delta method (Papanicolaou):
Using the univariate delta method for ̂, we get
Using the multivariate delta method for ̂, let = ( , ):
According to the central limit theorem:
where Ʃ = ( () (,̂) (,̂) (̂) )
(∇ (̂)) = ( − Then,
So,
Hence,
By the same approach as (25), we get Therefore,
From (25), (30), and (34), the Variance-Covariance matrix for the Weibull distribution is:
The parameters and their variations can be generated from (8), (11), (19), and (25). We rely on SAS to do the calculation.
SAS output for parameters covariance matrix is presented in Appendix D.
The survival function is given in (23). This model is conducted from the survival times of all patients, regardless of any factor. This model cannot be applied to predict survival time for new patients because it treats everyone the same. Obviously, the survival time for an 18-year-old girl who is at the first stage of cancer cannot be the same as a 40-year-old woman who is at the last stage. Therefore, using the model in (23) covariates existing in the model, the more robust our model is and the less error we will experience in our predictions.
A model with covariates
The technique used to incorporate covariates into our survival model is the Accelerated Failure Time model (AFT).
The AFT model assumes the following relationship between two individuals i and j:
where ci, j is a constant that is specific to the pair of individuals (i, j) (Allison) A special case of this model is:
log( ) = 0 + 1 1 + 2 2 + ⋯ + + (37)
where 0 , 1 , … , , and σ are the parameters, 1 , 2 , … , are the values of covariates, ε is a random variable that is independently and identically distributed. In our case, Ti follows the Weibull distribution, so ε follows the standard extreme value distribution (Allison) .
The survival function of T at covariate values ( 1 , 2 , … , ) is: where x1 = AGE_DX, x2 = z1, x3 = z2, x4 = z3, x5 = SURGERY, x6 = RADIATION, x7 = BOTH
Evaluating model fit
The use of the obtained statistical model to make a conclusion and prediction is based on the verification that the model fits the data well. To check the validity, goodness of fit, and the assumptions of the proposed distributional survival model, we perform the test suggested by Paul Allison. We observe that the plot of log [− (̂( ))] versus log(t) is a straight line indicating that the assumptions of Weibull model is good fit to estimate the survival times of the African American breast cancer patients. The plot is presented in Appendix D.
DISCUSSION
The result of variancecovariance matrix in (35) is presented in Appendix D. This matrix shows us how much the estimates of α and λ can vary. The values in this matrix are very small. This means our model is very accurate.
The model (23) does not provide us much information as discussed above. It estimates the general patients' survival time. From this model, most questions about the general African American breast cancer patients can be answered. For example, the probability that a random African American breast cancer patient can survive 10 years after diagnosis is S(10) = 71.98%.
The probability that a patient will die at the 40 th month given that she has survived up to that time is h(40/12) = 86.51% (hazard function) .
The Accelerated Failure time model (40) gives us a lot of important information. All the covariates in this model are significant except for the RADIATION. This suggests that 1. Age, stage of cancer, treatment by only surgery, treatment by both surgery and radiation all affect patients' survival time.
2. Age contributes negatively to survival time and coefficients of stages are more negative when stages increase. This fits reality because younger patients can obviously resist illnesses better and a higher stage means shorter time of survival.
3. There is insufficient evidence to claim that radiation-only treatment can improve patients' survival time.
In contradiction to the model (23), model (40) helps us predict the survival time of a specific patient rather than the general population. Given a patient's specific information, we can generate a new survival function for that patient, which looks similar to model (23). For example, a 40-year-old woman who was diagnosed at the second stage, and was treated with only surgery has survival function:
Further prediction about this patient can be inferred easily from this model.
CONCLUSION AND RECOMMENDATIONS
Both model (23) and (40) Model (40) has a wider application. As discussed above, it helps predict the survivability of African American breast cancer patients. This model can be used in consulting activity.
Clinics need information from this model to determine the best treatments for their patients and to provide patients with their predicted survival status. Survival distribution can also be useful information for the insurance industry. The model can certainly be adjusted easily in particular situations. For example, in the case that clinics want more information about other types of treatment, more covariates can be added to the model by the same process. If information about other races is needed, the whole data from SEER will be taken, and race becomes a new covariate in our model.
Model (40) also provides us with many interesting findings that require more investigations. The confidence interval for the coefficient for this variable is (-0.1694, 0.0489) which lies mostly on the negative side. So it is suspicious that using only radiation in fact shortens patients' survival time. Two questions are raised here:
1. Should the radiation-only treatment be used for African American breast patients?
2. Do other races have the same problem with using only radiation?
The second question can be answered by using the same process in other races with the data from SEER. The second question suggests more research in the medical field. 
